U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06846853) titled 'Gadopiclenol Vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (magnetic Resonance Imaging)' on Feb. 20.
Brief Summary: This study will evaluate the efficacy and safety of Gadopiclenol, an FDA-approved contrast agent, for visualizing pituitary lesions on MR images by comparing with the comparator, Gadobutrol, a clinically widely used contrast agent. The study is double-blinded, so neither the participants nor the researchers know which contrast agent is being used during each scan to avoid the bias of results.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Contrast Enhanced Images Vs. Non-contrast Imag...